The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Kim, Hyoung Jin ^a   Lim, Su Jeung ^a   Kwag, Hye Lim ^a   Kim, Hong Jin ^a  

^a Chung Ang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; WART VIRUS VACCINE; LIGAND; MONOCLONAL ANTIBODY; RESIN;

ANIMAL EXPERIMENT; ARTICLE; CD3+ T LYMPHOCYTE; CHROMATOGRAPHY; CONTROLLED STUDY; FEMALE; HEPARIN CHROMATOGRAPHY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNOGENICITY; INTERMETHOD COMPARISON; ION EXCHANGE CHROMATOGRAPHY; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PURIFICATION; VIRUS LIKE AGENT; AFFINITY CHROMATOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; VIRION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CHROMATOGRAPHY, AFFINITY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION; LIGANDS; MICE; MICE, INBRED BALB C; RESINS, SYNTHETIC; VIRION;

EID: 84860354190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035893     Document Type: Article

References (49)

1. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL, (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 (Suppl 3): S3/26-34.
2. Conway MJ, Meyers C, (2009) Replication and assembly of human papillomaviruses. J Dent Res 88: 307-317.
3. Bishop B, Dasgupta J, Klein M, Garcea RL, Christensen ND, et al. (2007) Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 282: 31803-31811.
4. Madrid-Marina V, Torres-Poveda K, Lopez-Toledo G, Garcia-Carranca A, (2009) Advantages and disadvantages of current prophylactic vaccines against HPV. Arch Med Res 40: 471-477.
5. de Witte L, Zoughlami Y, Aengeneyndt B, David G, van Kooyk Y, et al. (2007) Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology 212: 679-691.
6. Opalka D, Matys K, Bojczuk P, Green T, Gesser R, et al. (2010) Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17: 818-827.
7. Selinka HC, Giroglou T, Nowak T, Christensen ND, Sapp M, (2003) Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 77: 12961-12967.
8. Mirano-Bascos D, Steede NK, Robinson JE, Landry SJ, (2010) Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120. J Virol 84: 3303-3311.
9. Dai G, Steede NK, Landry SJ, (2001) Allocation of helper T-cell epitope immunodominance according to three-dimensional structure in the human immunodeficiency virus type I envelope glycoprotein gp120. J Biol Chem 276: 41913-41920.
10. Schiller JT, Day PM, Kines RC, (2010) Current understanding of the mechanism of HPV infection. Gynecol Oncol 118: S12-17.
11. Day PM, Garnbhira R, Roden RBS, Lowy DR, Schiller JT, (2008) Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. Journal of Virology 82: 4638-4646.
12. Kim SN, Jeong HS, Park SN, Kim H-J, (2007) Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J Virol Methods 139: 24-30.
13. Aires KA, Cianciarullo AM, Carneiro SM, Villa LL, Boccardo E, et al. (2006) Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 72: 745-752.
14. Buonamassa DT, Greer CE, Capo S, Yen TS, Galeotti CL, et al. (2002) Yeast coexpression of human papillomavirus types 6 and 16 capsid proteins. Virology 293: 335-344.
15. Kim HJ, Kim SY, Lim SJ, Kim JY, Lee SJ, et al. (2010) One-step chromatographic purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 70: 68-74.
16. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT, (2005) Maturation of papillomavirus capsids. J Virol 79: 2839-2846.
17. Moyer AL, Pumphrey KA, Anderson DE, Dvoretzky I, Buck CB, (2010) Endpoint maturation of the papillomavirus virion. 26th internaltional papillomavirus conference.
18. Zhao Q, Guo HH, Wang Y, Washabaugh MW, Sitrin RD, (2005) Visualization of discrete L1 oligomers in human papillomavirus 16 virus-like particles by gel electrophoresis with Coomassie staining. J Virol Methods 127: 133-140.
19. Cook JC, Joyce JG, George HA, Schultz LD, Hurni WM, et al. (1999) Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr Purif 17: 477-484.
20. Park MA, Kim HJ, Kim H-J, (2008) Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 59: 175-181.
21. Park JY, Pyo HM, Yoon SW, Baek SY, Parz SN, et al. (2002) Production and prophylactic efficacy study of human papillomavirus-like particle expressing HPV16 L1 capsid protein. Journal of Microbiology 40: 313-318.
22. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, et al. (1999) Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73: 4882-4889.
23. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, et al. (2001) Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291: 324-334.
24. Rizk RZ, Christensen ND, Michael KM, Muller M, Sehr P, et al. (2008) Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89: 117-129.
25. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA, (2003) Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 77: 11625-11632.
26. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC, (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5: 557-567.
27. Thones N, Herreiner A, Schadlich L, Piuko K, Muller M, (2008) A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 82: 5472-5485.
28. Conway MJ, Alam S, Ryndock EJ, Cruz L, Christensen ND, et al. (2009) Tissue-spanning redox gradient-dependent assembly of native human papillomavirus type 16 virions. J Virol 83: 10515-10526.
29. Mach H, Volkin DB, Troutman RD, Wang B, Luo Z, et al. (2006) Disassembly and reassembly of yeast-derived recombinant human papillomavirus virus-like particles (HPV VLPs). J Pharm Sci 95: 2195-2206.
30. Shi L, Sanyal G, Ni A, Luo Z, Doshna S, et al. (2005) Stabilization of human papillomavirus virus-like particles by non-ionic surfactants. J Pharm Sci 94: 1538-1551.
31. Schadlich L, Senger T, Kirschning CJ, Muller M, Gissmann L, (2009) Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 27: 1511-1522.
32. Zhang Y, Stastny P, (2006) MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity. Hum Immunol 67: 215-222.
33. Ishikawa-Sekigami T, Kaneko Y, Okazawa H, Tomizawa T, Okajo J, et al. (2006) SHPS-1 promotes the survival of circulating erythrocytes through inhibition of phagocytosis by splenic macrophages. Blood 107: 341-348.
34. Culp TD, Spatz CM, Reed CA, Christensen ND, (2007) Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361: 435-446.
35. Ryding J, Dahlberg L, Wallen-Ohman M, Dillner J, (2007) Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 88: 792-802.
36. Montefiori DC, Mascola JR, (2009) Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr Opin HIV AIDS 4: 347-351.
37. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
38. Ros C, Gerber M, Kempf C, (2006) Conformational changes in the VP1-unique region of native human parvovirus B19 lead to exposure of internal sequences that play a role in virus neutralization and infectivity. J Virol 80: 12017-12024.
39. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, et al. (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci U S A 95: 1800-1805.
40. Schellenbacher C, Roden R, Kirnbauer R, (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83: 10085-10095.
41. Schwarz TF, (2009) Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 26: 983-998.
42. Vicente T, Roldao A, Peixoto C, Carrondo MJT, Alves PM, (2011) Large-scale production and purification of VLP-based vaccines. Journal of Invertebrate Pathology 107: S42-S48.
43. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI, (2005) Towards the preparative and large-scale precision manufacture of virus-like particles. Trends in Biotechnology 23: 523-529.
44. Kim HJ, Lee SJ, Kim H-J, (2010) Optimizing the secondary structure of human papillomavirus type 16 L1 mRNA enhances L1 protein expression in Saccharomyces cerevisiae. J Biotechnol 150: 31-36.
45. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
46. Buck CB, Pastrana DV, Lowy DR, Schiller JT, (2004) Efficient intracellular assembly of papillomaviral vectors. J Virol 78: 751-757.
47. Sun J, Song X, Hu S, (2008) Ginsenoside Rg1 and aluminum hydroxide synergistically promote immune responses to ovalbumin in BALB/c mice. Clin Vaccine Immunol 15: 303-307.
48. Woo MK, Hur SJ, Park S, Kim H-J, (2007) Study of cell-mediated response in mice by HPV16 L1 virus-like particles expressed in Saccharomyces cerevisiae. J Microbiol Biotechnol 17: 1738-1741.
49. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, et al. (2004) Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321: 205-216.